These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20663134)

  • 1. HIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation.
    Monsef N; Soller M; Panagopoulos I; Abrahamsson PA
    BMC Cancer; 2010 Jul; 10():385. PubMed ID: 20663134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
    Monsef N; Helczynski L; Lundwall A; Påhlman S;
    Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
    Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
    Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
    Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
    Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
    Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
    Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
    Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
    Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
    Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
    Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
    Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
    Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues.
    Wei H; Desouki MM; Lin S; Xiao D; Franklin RB; Feng P
    Mol Cancer; 2008 Jan; 7():7. PubMed ID: 18208603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer.
    Straub B; Müller M; Krause H; Schrader M; Miller K
    Urology; 2003 Jul; 62(1):172-6. PubMed ID: 12837461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human pHyde is not a classical tumor suppressor gene in prostate cancer.
    Porkka KP; Nupponen NN; Tammela TL; Vessella RL; Visakorpi T
    Int J Cancer; 2003 Sep; 106(5):729-35. PubMed ID: 12866033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.
    Cordon-Cardo C; Koff A; Drobnjak M; Capodieci P; Osman I; Millard SS; Gaudin PB; Fazzari M; Zhang ZF; Massague J; Scher HI
    J Natl Cancer Inst; 1998 Sep; 90(17):1284-91. PubMed ID: 9731735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression and localisation of beta-nerve growth factor (beta-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation.
    Paul AB; Grant ES; Habib FK
    Br J Cancer; 1996 Dec; 74(12):1990-6. PubMed ID: 8980402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer.
    Harries LW; Perry JR; McCullagh P; Crundwell M
    BMC Cancer; 2010 Jun; 10():315. PubMed ID: 20569440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreactivity of ubiquitin in human prostate gland.
    Bataineh ZM; Habbal O
    Neuro Endocrinol Lett; 2006 Aug; 27(4):517-22. PubMed ID: 16892003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
    Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.
    Bonkhoff H
    Prostate Suppl; 1998; 8():18-22. PubMed ID: 9690659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
    Lin B; Utleg AG; Gravdal K; White JT; Halvorsen OJ; Lu W; True LD; Vessella R; Lange PH; Nelson PS; Hood L; Kalland KH; Akslen LA
    Clin Cancer Res; 2008 Mar; 14(5):1397-406. PubMed ID: 18316561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence.
    Ito T; Yamamoto S; Ohno Y; Namiki K; Aizawa T; Akiyama A; Tachibana M
    Oncol Rep; 2001; 8(6):1221-4. PubMed ID: 11605036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.